Research Department of Infection and Population Health, UCL Medical School, London, UK.
AIDS. 2010 Mar 13;24(5):723-7. doi: 10.1097/QAD.0b013e328333fa0f.
To identify a definition of presentation after clinical or immunological disease progression that will reliably identify an individual at high risk of mortality over the first 3 months after HIV diagnosis and that can be adopted as a basis for comparing over time and regions.
An observational cohort study.
Individuals seen for the first time at a UK Collaborative HIV Cohort study clinic from 1996 to 2006 were identified. Two immunological (CD4 cell count < 200 cells/microl and CD4 cell count <50 cells/microl) and two clinical (AIDS and severe/moderate AIDS) criteria for presentation with advanced HIV disease were compared, as well as combinations of them. The predictive ability of each diagnosis for identifying individuals who died in the first 3 months after HIV diagnosis was assessed.
Fifteen thousand seven hundred and seventy-four patients were included, of whom 1495 (9.5%), 4231 (26.8%), 1523 (9.7%) and 379 (2.4%) had a CD4 cell count below 50 cells/microl, CD4 cell count below 200 cells/microl, AIDS or severe/moderate AIDS at diagnosis; CD4 cell counts were unavailable for 2264 (14.4%) patients. Two hundred and six (1.3%) patients died within the first 3 months. Sensitivities of the individual criteria ranged from 18.0% (severe/moderate AIDS) to 50.5% (CD4 cell count < 200 cells/microl) with specificities ranging from 73.5% (CD4 < 200 cells/microl) to 97.8% (severe/moderate AIDS). Combinations of clinical and immunological criteria increased the sensitivity but decreased the specificity.
We propose that presentation with 'advanced HIV disease' is presentation with a CD4 cell count below 200 cells/microl or AIDS, whereas 'late' presentation is defined as presentation when the CD4 cell count is below that when treatment should be initiated (currently CD4 cell count < 350 cells/microl or AIDS).
确定在临床或免疫疾病进展后出现的表现定义,以便可靠地识别出在 HIV 诊断后 3 个月内死亡风险较高的个体,并将其作为随时间和地区进行比较的基础。
观察性队列研究。
从 1996 年至 2006 年在英国协作性 HIV 队列研究诊所首次就诊的个体被确定。比较了两种免疫(CD4 细胞计数<200 个/微升和 CD4 细胞计数<50 个/微升)和两种临床(艾滋病和严重/中度艾滋病)的晚期 HIV 疾病出现标准,以及它们的组合。评估每种诊断方法识别 HIV 诊断后 3 个月内死亡个体的能力。
共纳入 15774 例患者,其中 CD4 细胞计数<50 个/微升、CD4 细胞计数<200 个/微升、艾滋病或严重/中度艾滋病的患者分别为 1523 例(9.7%)、4231 例(26.8%)和 1495 例(9.5%),379 例(2.4%);CD4 细胞计数不可用的患者为 2264 例(14.4%)。1 至 3 个月内有 206 例(1.3%)患者死亡。各标准的灵敏度范围为 18.0%(严重/中度艾滋病)至 50.5%(CD4 细胞计数<200 个/微升),特异性范围为 73.5%(CD4 细胞计数<200 个/微升)至 97.8%(严重/中度艾滋病)。临床和免疫标准的组合提高了灵敏度,但降低了特异性。
我们建议“晚期 HIV 疾病”的表现定义为 CD4 细胞计数<200 个/微升或艾滋病,而“晚期”的表现定义为 CD4 细胞计数下降至应开始治疗的水平(目前为 CD4 细胞计数<350 个/微升或艾滋病)时。